(Q37276915)

19 August 2017

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis (English)

1 reference

low-grade serous carcinoma

19 August 2017

0 references

high-grade serous carcinoma

0 references

author name string

Ayse Ayhan

1

1 reference

19 August 2017

Robert J Kurman

2

1 reference

19 August 2017

Anna Yemelyanova

3

1 reference

19 August 2017

Russell Vang

4

1 reference

19 August 2017

Sanjay Logani

5

1 reference

19 August 2017

Jeffrey D Seidman

6

1 reference

19 August 2017

Ie-Ming Shih

7

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

The American Journal of Surgical Pathology

19 August 2017

1 reference

19 August 2017

33

1 reference

19 August 2017

8

1 reference

19 August 2017

1220-1224

1 reference

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Diverse tumorigenic pathways in ovarian serous carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

PIK3CA mutations in advanced ovarian carcinomas

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716424

Grading ovarian serous carcinoma using a two-tier system

3 September 2018

1 reference

12 December 2020

Classification and Staging of Malignant Tumours in the Female Pelvis

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

1 reference

12 December 2020

Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma

1 reference

12 December 2020

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

1 reference

12 December 2020

10.1097/PAS.0B013E3181A24354

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19461510

1 reference